Trends & Analysis
SITC 2026: Immune Mechanisms, Core Targets & Emerging Therapies
This report analyzes the 41st SITC Annual Meeting (2026), covering 1,065 regular abstracts, 42 award abstracts and 19 late-breaking abstracts. Key signals include tumor-localized conditional activation, costimulation-enhanced T-cell engagers, the PD-1×VEGF bispecific race, in vivo cell engineering and biparatopic ADCs, with competitive hotspots across PD-1/PD-L1, CD3, VEGF, GPC3, STEAP2, PSMA, KRAS and IL-12.

Overview
Based on SITC 2026 public abstracts and the JITC supplements, this report provides a structured view of immuno-oncology innovation, moving from conference-level statistics to late-breaking clinical evidence and then to a modality-by-modality target analysis. It covers mAbs and multispecifics, T-cell engagers, CAR platforms, ADCs, TCR-T and cytokine-based therapies, and tracks the shared design logic emerging across them: localizing activity to the tumor, recruiting non-conventional effector cells, and broadening antigen recognition while controlling systemic toxicity. With most studies still preclinical or early clinical, the report also flags where evidence maturity, trial design and population differences limit cross-study comparison, offering reference value for target prioritization, preclinical model selection and BD assessment.
Key Insights
Selected SITC 2026 abstracts covering immune mechanisms, therapeutic modalities, target landscapes and clinical translation.
- Key innovation areas: costimulation-enhanced and conditionally activated T-cell engagers, PD-1×VEGF bispecifics, in vivo CAR-T/CAR-M/CAR-B/CAR-Treg and in vivo TCR-T, biparatopic and immune-cell-directed ADCs, therapeutic vaccines, allogeneic NK and intratumoral siRNA.
- Major focus targets: PD-1/PD-L1, CD3, CD28/4-1BB/CD2 costimulation, VEGF, GPC3, STEAP2, PSMA, KLK2, B7-H3, MSLN, KRAS, TREM2, OX40, BTN1A1/BTN3A, IL-18BP and IL-12/IL-27, with activity concentrated in NSCLC, prostate cancer, HCC, melanoma, breast cancer and multiple myeloma.
- Emerging trend: engineering is moving inside the body, as mRNA-LNP and targeted viral delivery turn cell therapy into an in vivo process, while conditional activation and local delivery decouple antitumor activity from systemic exposure.
- Strategic value: supports target prioritization, humanized and tumor model selection for preclinical validation, and early assessment of competitive and licensing opportunities in immuno-oncology.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
